Compositions comprising antisense-encoded erythropoietin receptor and use thereof
Provided herein are nanoparticles comprising antisense-encoded erythropoietin receptor (RopE) alone or in combination with erythropoietin receptor (EpoR). Also provided herein are methods of treating or preventing lungs disorders comprising administering RopE alone or in combination with EpoR.
1. A nanoparticle comprising antisense-encoded erythropoietin receptor (RopE) protein and/or a nucleic acid encoding RopE, wherein said nanoparticle does not contain erythropoietin receptor (EpoR) protein and/or a nucleic acid encoding EpoR.
2. The nanoparticle of claim 1 , wherein the nucleic acid is a messenger RNA (mRNA), a plasmid DNA (pDNA), or a complementary DNA (cDNA).
3. The nanoparticle of claim 1 , wherein the nanoparticle is a lipid-based nanoparticle, a superparamagnetic nanoparticle, a nanoshell, a semiconductor nanocrystal, a quantum dot, a polymer-based nanoparticle, a silicon-based nanoparticle, a silica-based nanoparticle, a metal-based nanoparticle, a fullerene or a nanotube.
4. The nanoparticle of claim 1 , wherein the nanoparticle is a poly(lactic-co-glycolic) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), or chitosan nanoparticle.
5. The nanoparticle of claim 1 , wherein the nanoparticle is a lipid-polymer hybrid nanoparticle.
6. The nanoparticle of claim 1 , wherein the nanoparticle is a lipid-PLGA hybrid nanoparticle.
7. The nanoparticle of claim 1 , further comprising a cryoprotectant.
8. The nanoparticle of claim 1 , wherein the nanoparticle has a diameter between 150 nm to 250 nm, or 100 nm to 200 nm, or 175 nm to 222 nm.
9. The nanoparticle of claim 1 , further comprising an imaging agent and/or a targeting molecule.
10. A pharmaceutical composition comprising nanoparticles according to claim 1 and a pharmaceutically acceptable excipient.
11. The composition of claim 10 , wherein the pharmaceutical composition is formulated for inhalation, aerosols, lung delivery, nasal delivery, airway instillation, oral administration, mucosal application, or vascular injection into a vein or artery.
12. A method for treating a lung disorder in a subject comprising administering a therapeutically effective amount of an antisense-encoded erythropoietin receptor (RopE) protein and/or a nucleic acid encoding RopE to the subject, wherein said method does not comprise administering erythropoietin receptor (EpoR) protein and/or a nucleic acid encoding EpoR.
13. The method of claim 12 , wherein said RopE protein or nucleic acid is formulated in a nanoparticle.
14. The method of claim 13 , wherein the nanoparticle is a lipid-based nanoparticle, a superparamagnetic nanoparticle, a nanoshell, a semiconductor nanocrystal, a quantum dot, a polymer-based nanoparticle, a silicon-based nanoparticle, a silica-based nanoparticle, a metal-based nanoparticle, a fullerene or a nanotube.
15. The method of claim 13 , wherein the nanoparticle is a poly(lactic-co-glycolic) (PLGA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), or chitosan nanoparticle.
16. The method of claim 13 , wherein the nanoparticle is a lipid-polymer hybrid nanoparticle.
17. The method of claim 13 , wherein the nanoparticle is a lipid-PLGA hybrid nanoparticle.
18. The method of claim 13 , wherein the nanoparticle has a diameter between 150 nm to 250 nm, or 100 nm to 200 nm, or 175 nm to 222 nm.
19. The method of claim 13 , wherein the nanoparticle further comprises an imaging agent and/or a targeting molecule.
20. The method of claim 12 , wherein the nucleic acid is a messenger RNA (mRNA), a plasmid DNA (pDNA), or a complementary DNA (cDNA).
21. The method of claim 12 , wherein administering comprises inhalation, aerosol delivery, lung delivery, nasal delivery, airway instillation, oral administration, mucosal application, or vascular injection into a vein or artery.